Clinical Trial Update: Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating safety and symptom burden optimization of tocilizumab as part of ASCT conditioning for multiple myeloma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Multiple Myeloma | Phase 4 | Status: UNKNOWN